SciSparc's NeuroThera expands US patent filings on psychedelic-PEA combinations with Clearmind
Three new US patent applications cover LSD, ketamine and ibogaine paired with NeuroThera's PEA technology for conditions including depression, PTSD and substance use disorders.
SciSparc Ltd. (Nasdaq: SPRC) announced on September 23, 2026 that its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) highlighted the expansion of the U.S. intellectual property portfolio through its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND).1
As part of the collaboration, three U.S. patent applications have been published covering novel combinations of lysergic acid diethylamide, ketamine and ibogaine with N-acylethanolamines, including palmitoylethanolamide, NeuroThera's proprietary technology.1 The applications cover potential therapeutic uses across a range of indications, including mental health disorders such as depression and post-traumatic stress disorder, as well as pain and substance use disorders.1
These filings build on previously announced intellectual property from the collaboration, including a U.S. patent application covering the combination of MDMA and N-acylethanolamines for potential treatment of PTSD, anxiety and eating disorders.1
The companies described the work as ongoing. NeuroThera and Clearmind continue to advance their collaboration, aimed at bringing safer and more effective treatments to market for some of the most common and rapidly growing mental-health conditions, with a continued focus on combining PEA with psychedelic-derived compounds while enhancing the intellectual property portfolio.1
Regarding corporate structure, SciSparc, through its subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments, with a focus on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.1 Together with its majority-owned subsidiary NeuroThera, SciSparc is currently engaged in drug development programs based on THC and/or non-psychoactive CBD, including SCI-110 for Tourette syndrome and for Alzheimer's disease and agitation, and SCI-210 for autism spectrum disorder and status epilepticus.1
The disclosure was filed as part of a Form 6-K report of foreign private issuer with the SEC, referencing SciSparc's Annual Report on Form 20-F, filed with the SEC on April 29, 2026, as amended.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.